9 news items
HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
SYRS
15 May 24
HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 price target.
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
SYRS
14 May 24
that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARĪ± agonist in frontline patients with higher-risk
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
ACB
ACRV
AMD
9 Apr 24
and a price target of $9.
Lyell Immunopharma, Inc
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
SYRS
9 Apr 24
to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARĪ±
Piper Sandler Reiterates Overweight on Syros Pharmaceuticals, Maintains $13 Price Target
SYRS
3 Apr 24
Piper Sandler analyst Edward Tenthoff reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Overweight and maintains $13 price target.
nl2tqvuvk471mzyr5g8t862qxy09js8ajshgq2whvv2mtlio0c82
SYRS
2 Apr 24
by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral
6qevf08w9
HUM
IRON
SYRS
2 Apr 24
will further reinforce tamibarotene’s potential as a differentiated, biologically targeted approach for the approximately 50% of HR-MDS patients
lhwfyv3ipzplqp4b jllsru2mjg9v1emm6m6hndxeg0703kuxjgat7tc
SYRS
27 Mar 24
potential as a differentiated, biologically targeted approach for the approximately 50% of HR-MDS patients who are positive
k3dzpw5lp
SYRS
25 Mar 24
is ongoing to reach the 550-patient target.
Syros is also evaluating tamibarotene in combination with venetoclax
- Prev
- 1
- Next